DUAL LSD1/HDAC INHIBITORS

The present disclosure provides a compound of Formula (I), its analogs, tautomeric forms, stereoisomers, enantiomers, diastereomers and pharmaceutically acceptable salts thereof. The present disclosure also provides a process for preparing the compounds of Formula (I), its analogs, tautomeric forms,...

Full description

Saved in:
Bibliographic Details
Main Authors GAJENDRAN, Chandru, SIVANANDHAN, Dhanalakshmi, RASTELLI, Luca, SADHU, Naveen, SRIDHARAN, Rajagopal
Format Patent
LanguageEnglish
Published 22.05.2025
Subjects
CHEMISTRY
HETEROCYCLIC COMPOUNDS
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online AccessGet full text

Cover

More Information
Summary:The present disclosure provides a compound of Formula (I), its analogs, tautomeric forms, stereoisomers, enantiomers, diastereomers and pharmaceutically acceptable salts thereof. The present disclosure also provides a process for preparing the compounds of Formula (I), its analogs, tautomeric forms, stereoisomers, enantiomers, diastereomers and pharmaceutically acceptable salts thereof. The compounds of Formula (I) modulates MYC or coREST, in a subject in need thereof. The compounds of Formula (I) inhibits HDAC enzymes or LSD1 enzymes, or both HDAC enzymes and LSD1 enzymes. The compound of Formula (I) is an epigenetic modulating agent with a novel mechanism of action that target MYC amplification in multiple neuroendocrine tumors types.
Bibliography:Application Number: US202318842771